跳至主要内容
临床试验/TCTR20220202004
TCTR20220202004Unknown1 期

Clinical and pathological response of pre-operative Intratumoral and Intramuscular Poly-ICLC(Hiltonol) for cutaneous melanoma stage 2 and 3

/A0 个研究点目标入组 12 人开始时间: 2022年2月2日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. diagnosed with cutaneous melanoma stage 2 and 3
  • 2. age more than 18 years old
  • 3. expected life expectancy more than 6 months
  • 4. ECOG 0-1
  • 5. inform-consent to be part of the research
  • 6. normal liver and kidneys functions as state in the protocol

排除标准

  • 1. allergy to poly-ICLC
  • 2. melanoma at face
  • 3. autoimmune disease
  • 4. history of immunologic treatment except antibody treatment and discontinue the drug more than 4 weeks
  • 5. history of CMT, RT, or targeted therapy and discontinue less than 2 weeks
  • 6. history of others carcinoma except BCC or SCC which can be treat locally
  • 7. HIV infection
  • 8. receive live attenuated vaccine and killed vaccine within 28 days before receiving 1st dose of poly-ICLC
  • 9. prescribed with prednisolone more than 10 mg per day except inhaled or intranasal corticosteroids
  • 10. any health issues the might interfere with the efficacy of the drug and/or harmful to one health associated with using poly-ICLC
  • 11. prenant women or lactation

研究者

发起方
/A

相似试验